

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/586,015
				Filing Date	August 4, 2008
				First Named Inventor	Eric T. Ahrens
				Art Unit	1618
				Examiner Name	Jagadishwar Rao Samala
Sheet	1	of	4	Attorney Docket Number	CAMU-P01-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/J.S./	AT1	2002/0192688	12-19-2002	Yang et al.	
	AU1	2004/0109824	06-10-2004	Hinds et al.	
	AV1	2005/0008572	01-13-2005	Prokop et al.	
	AW1	2005/0244384	11-03-2005	Law	
	AX1	2006/0040389	02-23-2006	Murry et al.	
	AY1	2006/0239919	10-26-2006	Wickline et al.	
	AX1	2007/0253910	11-01-2007	Ahrens et al.	
	AA2	2007/0258886	11-18-2007	Ahrens et al.	
	AB2	2009/0263329	10-22-2009	Wickline et al.	
	AC2	4,094,911	06-13-1978	Zollinger	
	AD2	5,785,950	07-28-1998	Kaufman et al.	
	AE2	5,958,371	09-28-1999	Lanza et al.	
	AF2	7,357,937	04-15-2008	Hsu et al.	
/J.S./	AG2	7,514,074	04-07-2009	Pittinger et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
/J.S./	BK	EP 1 728 788	12-06-2006	Shinetsu Chemical Co.		
	BL	WO91/14664	10-03-1991	Hider et al.		
	BM	WO94/18954	09-01-1994	Clover Consolidated, Limited		
	BN	WO96/41647	12-27-1996	Barnes-Jewish Hospital		
	BO	WO97/40679	11-06-1997	Imarz Pharmaceuticals Corp.		
	BP	WO05/072780	08-11-2005	Carnegie Mellon University		
	BQ	WO06/096499	09-14-2006	Washington University		
	BR	WO07/100715	09-07-2007	Washington University		
	BS	WO08/119790	10-09-2008	Heinrich-Heine Universität Düsseldorf		
/J.S./	BT	WO09/009105	01-15-2009	Carnegie Mellon University		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/J.S./	CT1	ABLAMUNITS et al., Acceleration of autoimmune diabetes by cyclophosphamide is associated with an enhanced IFN-gamma secretion pathway, J. Autoimmun. 13(4):383-392 (1999)	
/J.S./	CU1	AHRENS et al., In vivo imaging platform for tracking immunotherapeutic cells, Nat. Biotechnol. 23(8):983-987 (2005)	
/J.S./	CV1	ALLEN et al., Cellular delivery of MRI contrast agents, Chem. Bio. 11(3):301-307 (2004)	
/J.S./	CW1	ANDERSON et al., Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis, Ann. Neurol. 55(5):654-659 (2004)	

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/586,015
				Filing Date	August 4, 2008
				First Named Inventor	Eric T. Ahrens
				Art Unit	1618
				Examiner Name	Jagadishwar Rao Samala
Sheet	2	of	4	Attorney Docket Number	CAMU-P01-002

/J.S./	CX1	ARABAB et al., Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI, Blood 15:104(4):1217-23 (2004)	
	CY1	BASSE-LUSEBRINK et al., Multi-color ¹⁹ F CSI: Simultaneous detection of differently labeled cells in vivo, Abstract #806, Proc. Int. Soc. Mag. Reson. 17 (2009)	
	CZ1	BILLOTEY et al., T-cell homing to the pancreas in autoimmune mouse models of diabetes: in vivo MR imaging, Radiology 236(2):579-587 (2005)	
	CA2	BULTE et al., Preparation of magnetically labeled cells for cell tracking by magnetic resonance imaging. Method Enzymol. 386:275-299 (2004)	
	CB2	CANTOR et al., Effector function of diabetogenic CD4 Th1 T cell clones: a central role for TNF-alpha, J. Immunol. 175(11):7738-7745 (2005)	
	CC2	CARUTHERS et al., In vitro demonstration using ¹⁹ F magnetic resonance to augment molecular imaging with paramagnetic perfluorocarbon nanoparticles at 1.5 Tesla, Invest. Radiology 41(3):305-311 (2006)	
	CD2	CHENG et al., Characterization of aqueous dispersions of Fe(3)O(4) nanoparticles and their biomedical applications, Biomaterials 26(7):729-738 (2005)	
	CE2	CROWDER, et al. "Unique perfluorocarbon nanobeacons improve stem/progenitor cell tracking with MRI" FASEB Journal, vol. 20, no. 4, part 1, March 2006, pp.A633, Abstract.	
	CF2	CUNNINGHAM et al., Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles, Mag. Res. In Med. 53:999-1005 (2005)	
	CG2	ELSTER et al., Dyke Award. Europium-DTPA: a gadolinium analogue traceable by fluorescence microscopy, Am. J. Neuroradiol. 10(6):1137-1144 (1989)	
	CH2	EVGENOV et al., In vivo imaging of immune rejection in transplanted pancreatic islets, Diabetes 55(9):2419-2428 (2006)	
	CI2	EVGENOV et al., In vivo imaging of islet transplantation, Nat. Med. 12(1):144-148 (2006)	
	CJ2	FABIEN et al., Pancreatic lymph nodes are early targets of T cells during adoptive transfer of diabetes in NOD mice, J. Autoimmun. 8(3):323-334 (1995)	
	CK2	FAN et al., MRI of perfluorocarbon emulsion kinetics in rodent mammary tumours, Phys. Med. & Biol. 51:211-220 (2006)	
	CL2	FLOGEL et al., In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging, Circulation 118:140-148 (2008)	
	CM2	FLORIS et al., Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study, Brain. 127(Pt 3):616-27 (2004)	
	CN2	GRANOT et al., Labeling fibroblasts with biotin-BSA-GdDTPA-FAM for tracking of tumor-associated stroma by fluorescence and MR imaging, Magn. Reson. Med. 54(4):789-797 (2005)	
	CO2	GUDBJARTSSON et al., The Rician distribution of noisy MRI data, Magn. Reson. Med. 34(6):910-914 (1995)	
	CP2	HELMER et al. On the correlation between the water diffusion coefficient and oxygen tension in RIF-1 tumors, NMR in Biomedicine, 11(3):120-130 (1998)	
	CQ2	HITCHENS et al., Comparison of iron-oxide- and perfluorocarbon-based cellular contrast agents for detecting immune cell infiltration in models of organ transplant rejection, Abstract #931, Proc. Int. Soc. Mag. Reson. 17 (2009)	
	CR2	JANJIC et al., Self-delivering nanoemulsions for dual fluorine-19 MRI and fluorescence detection, J. Amer. Chem. Soc. 130:2832-2841 (2008)	
	CS2	JIANG et al., The Design and Synthesis of Highly Branched and Spherically Symmetric Fluorinated Oils and Amphiles, Tetrahedron 63(19):3982-3988 (2007)	
	CT2	KIM et al., Interplay of tumor vascular oxygenation and tumor pO2 observed using near-infrared spectroscopy, an oxygen needle electrode, and ¹⁹ F MR pO2 mapping, J. Biomed Opt 8:53-62 (2003)	
↓	CU2	KIRCHER et al., In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors, Cancer Res. 63(20):6838-6846 (2003)	
/J.S./	CV2	KLUG et al., ¹ H/ ¹⁹ F molecular MR-imaging in mouse models of acute and chronic inflammation, Abstract #3172, Proc. Int. Soc. Mag. Reson. 17 (2009)	

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/586,015
				Filing Date	August 4, 2008
				First Named Inventor	Eric T. Ahrens
				Art Unit	1618
				Examiner Name	Jagadishwar Rao Samala
Sheet	3	of	4	Attorney Docket Number	CAMU-P01-002

↓	J.S./	CW2	KRAITCHMAN et al., In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction, <i>Circulation</i> 107(18):2290-2293 (2003)
		CX2	KRAVITZOFF et al., GD-DOTA Loaded into red blood cells. A new magnetic resonance imaging contrast agents for vascular system," <i>Adv. in Exp. Med. and Biol.</i> 326:347-326 (1992)
		CY2	LANZA et al., 1H/19F magnetic resonance molecular imaging with perfluorocarbon nanoparticles, In: Ahrens ET, editor. <i>In vivo cellular and molecular imaging</i> , Curr. Top. Dev. Biol. 70:58-78 (2005)
		CZ2	LANZA et al., A novel site-targeted ultrasonic contrast agent with broad biomedical application, <i>Circulation</i> 94(12):3334-3340 (1996)
		CA3	LAUKEMPER-OSTENDORF et al., 19F-MRI of perflubron for measurement of oxygen partial pressure in porcine lungs during partial liquid ventilation, <i>Magn. Reson. Med.</i> 47:82-89 (2002)
		CB3	LEITER et al., The nonobese diabetic (NOD) mouse, <i>Am. J. Pathol.</i> 128(2):380-383 (1987)
		CC3	MASON et al., Hexafluorobenzene: a sensitive 19F NMR indicator of tumor oxygenation, <i>NMR Biomed</i> 9:125-134 (1996)
		CD3	McNAB et al., Tissue oxygen tension measurements in the Shionogi model of prostate cancer using 19F MRS and MRI, <i>MAGMA</i> 17:288-295 (2004)
		CE3	MEYER et al., Measurement of vascular volume in experimental rat tumors by 19F magnetic resonance imaging, <i>Invest. Radiol.</i> 28(8):710-719 (1993)
		CF3	MILLER et al., Imaging the single cell dynamics of CD4+ T cell activation by dendritic cells in lymph nodes, <i>J. Exp. Med.</i> 200(7):847-856 (2004)
		CG3	MIYAZAKI et al., Predominance of lymphocytes-T in pancreatic-islets and spleen of pre-diabetic non-obese diabetic (NOD) mice - a longitudinal-study, <i>Clin. Exp. Immunol.</i> 60(3):622-63 (1985)
		CH3	MODO et al., Mapping transplanted stem cell migration after a stroke: a serial, in vivo magnetic resonance imaging study, <i>Neuroimage</i> 21(1):311-31 (2004)
		CI3	MOORE et al., Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time, <i>Diabetes</i> 53(6):1459-1466 (2004)
		CJ3	MORAWSKI et al., Quantitative magnetic resonance immunohistochemistry with ligand-targeted F-19 nanoparticles, <i>Magn. Reson. Med.</i> 52(6):1255-126 (2004)
		CK3	MORAWSKI et al., Targeted Nanoparticles for Quantitative Imaging of Sparse Molecular Epitopes with MRK, <i>Mag. Res. in Med.</i> 51(3):480-486 (2004)
		CL3	NEUBAUER et al., Endothelial stem cell detection in vivo with unique perfluorocarbon nanoparticle labels using fluorine (F-19) MNRI at 1.5 T, <i>Circulation</i> 114(18)(Suppl. S): 251 (Abstract) (2006)
		CM3	PAKALA et al., helper 2 (Th2) T cells induce acute pancreatitis and diabetes in immune-compromised nonobese diabetic (NOD) mice, <i>J. Exp. Med.</i> 186(2):299-306 (1997)
		CN3	PARTLOW et al., 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons, <i>FASEB J.</i> 21:1647-1651 (2007)
		CO3	PELCHEN-MATTHEWS et al., Phorbol ester-induced downregulation of CD4 is a multistep process involving dissociation from p56lck, increased association with clathrin-coated pits, and altered endosomal sorting, <i>J. Exp. Med.</i> 178(4):1209-1222 (1993)
		CP3	PHILLIPS et al., MAdCAM-1 is needed for diabetes development mediated by the T cell clone, BDC-2.5, <i>Immunology</i> 116(4):525-53 (2005)
	CQ3	PHILLIPS et al., Nondepleting anti-CD4 has an immediate action on diabetogenic effector cells, halting their destruction of pancreatic beta cells, <i>J. Immunol.</i> 165(4):1949-1955 (2000)	
	CR3	PIACENTI et al., Synthesis and characterization of fluorinated polyetheric amides, <i>J. Fluor. Chem.</i> 68:227-235 (1994)	
	CS3	PINTASKE et al., A preparation technique for quantitative investigation of SPIO-containing solutions and SPIO-labelled cells by MRI, <i>Biomed. Tech.</i> 50(6):174-180 (2005) (English Abstract)	
J.S./	CT3	RIBEIRO et al., In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: why are CD4+ but not CD8+ T cells depleted? <i>Proc. Natl. Acad. Sci. USA</i> 99(24):15572-15577 (2002)	

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/586,015
				Filing Date	August 4, 2008
				First Named Inventor	Eric T. Ahrens
				Art Unit	1618
				Examiner Name	Jagadishwar Rao Samala
Sheet	4	of	4	Attorney Docket Number	CAMU-P01-002

	CU3	RODRIGUEZ et al., In vitro characterization of an Fe(8) cluster as potential MRI contrast agent, NMR Biomed. 18(5):300-307 (2005)	
/J.S./	CV3	SCHNEIDER et al., In vivo microscopic evaluation of the microvascular behavior of FITC-labeled macromolecular MR contrast agents in the hamster skinfold chamber, Invest. Radiol. 35(9):564-570 (2000)	
	CW3	SHAPIRO et al., In vivo detection of single cells by MRI, Magn. Reson. Med. 55(2):242-249 (2006)	
	CX3	SOLOSKI, Synthesis of perfluoro (polyether) difunctional compounds, J. Fluor. Chem. 11:601-612 (1978)	
	CY3	SOTAK et al., A new perfluorocarbon for use on fluorine-19 magnetic resonance imaging and spectroscopy, Magn. Reson. Med. 29:188 (1993)	
	CZ3	SRINIVAS et al., Fluorine-19 MRI for visualization and quantification of cell migration in a diabetes model, Mag. Res. In Med. 58(4):725-733 (2007)	
	CA4	TAYLOR and DEUTSCH, 19F-nuclear magnetic resonance: measurements of [O2] and pH in biological systems, Biophys J. 53: 227-233 (1988)	
	CB4	TONELLI et al., Linear perfluoropolyether difunctional oligomers: chemistry, properties and applications, J. Fluorine Chem. 95:51-74 (1999)	
	CC4	TONELLI et al., Perfluoropolyether alkyl diesters: Structure effects of the alkyl group on the kinetics of the hydrolysis reactions, J. Polym. Sci. Part A: Polym Chem. 40:4266-4286 (2002)	
	CD4	TONELLI et al., Perfluoropolyether functional oligomers: unusual reactivity in organic chemistry, J. Fluor. Chem. 118(1-2):107-121 (2002)	
	CE4	TURVEY et al., Noninvasive imaging of pancreatic inflammation and its reversal in type 1 diabetes, J. Clin. Invest. 115(9):2454-2461 (2005)	
	CF4	VENANZI et al., Structural properties and photophysical behavior of conformationally constrained hexapeptides functionalized with a new fluorescent analog of tryptophan and a nitroxide radical quencher, Biopolymers 75(2):128-139 (2004)	
	CG4	WILSON et al., Measurement of preretinal oxygen-tension in the vitrectomized human eye using F-19 magnetic resonance spectroscopy, Arch. Ophthalmol-Chic. 110(8):1098-1100 (1992)	
	CH4	WISNER et al., A modular lymphographic magnetic resonance imaging contrast agent: contrast enhancement with DNA transfection potential, J. Med. Chem. 40(25):3992-3996 (1997)	
	CI4	WU et al., In situ labeling of immune cells with iron oxide particles: An approach to detect organ rejection by cellular MRI, Proc. Natl. Acad. Sci. USA 103(6):1852-1857 (2006)	
	CJ4	XIA et al., Tumour oxygen dynamics measured simultaneously by near-infrared spectroscopy and F-19 magnetic resonance imaging in rats, Phys. Med. Biol. 51(1):45-60 (2006)	
	CK4	YEH et al., Intracellular labeling of T-cells with superparamagnetic contrast agents, Magn. Reson. Med. 30(5):617-625 (1993)	
	CL4	YOU et al., Detection and characterization of T cells specific for BDC2.5 T cell-stimulating peptides, J. Immunol. 170(8):4011-4020 (2003)	
	CM4	YU et al., High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent, Mag. Res. In Med. 44:867-872 (2000)	
/J.S./	CN4	ZHANG et al., Synthetic applications of fluorous solid-phase extraction (F-SPE), Tetrahedron 62:11837-11865 (2006)	

Examiner Signature	/Jagadishwar Samala/ (11/14/2011)	Date Considered	
--------------------	-----------------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.